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Abstract
Background. A better understanding of molecular gastric cancer (GC) entities may help in tailored treatments 
of that neoplasm. The PIK3CA mutation is one of the most important in many cancers.
Objectives. We performed a comparison of clinical and pathological data of the PIK3CA mutation in GC 
patients.
Material and methods. The analysis was done on 472 patients operated on in 1 center. Polymerase chain 
reaction (PCR) was used for the screening of PIK3CA (exon 9 and 20). For microsatellite instability (MSI) we 
used 5 quasi-monomorphic mononucleotide repeats − BAT-26, BAT-25, NR-24, NR-21, and NR-27. The clinical 
and pathological data was analyzed.
Results. PIK3CA mutation was observed in 10 out of 472 GC patients (2.1%). Nine out of 10 were MSI 
(9 of 111 MSI patients – 8.1%). Half of the 10 patients had mutations in exon 9 and the other half in exon 20. 
A majority of patients with the PIK3CA mutation had MSI (p < 0.001). The 5-year survival of MSI patients 
with the PIK3CA mutation was 40% and without the mutation, 70.4% (p = 0.309). For patients with the 
mutation in exon 9, the 5-year survival was 0%, and for those with the mutation in exon 20, 80% (p = 0.031). 
The Cox proportional hazards regression analysis did not show that PIK3CA is statistically correlated with 
a worse overall survival.
Conclusions. PIK3CA mutation in GC is a rare finding. It  is strongly associated with the MSI molecular 
subgroup, presenting a worse outcome than other MSI patients. A completely different outcome is associated 
with the mutation in exon 9 compared to the mutation in exon 20, with the latter being more favorable.
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Introduction
Gastric cancer (GC) is a disease that is characterized 
by multiple molecular, genetic, and epigenetic events.1 Mu-
tation in a signaling pathway is one such event and the 
phosphoinositide 3-kinase (PI3K)/AKT/mammalian target 
of the rapamycin pathway (PI3K/AKT/mTOR pathway) 
is one example of the mutation mechanism.2 A fundamen-
tal step in this pathway is the creation of phosphatidylino-
sitol-3,4,5-triphosphatate (PIP3), catalyzed by PI3K. This 
pathway is important in the cancer-related functions of cell 
proliferation, catabolism, cell adhesion, apoptosis, and au-
tophagy.3 It also plays an important role in motility and 
glucose homeostasis.4 The mutations of this pathway have 
frequently been seen in cancers such as ovarian, breast, 
thyroid, and cervical. Many studies have revealed that 
this pathway is not of highest importance in GC patients. 
The  PIK3CA gene is  located on  chromosome 3p26.3.5 
The most common mutations are seen in exon 9 and 20, 
representing different hotspots of mutations.4
In the current literature, PIK3CA mutations in colorectal 
cancer (CRC) are associated with female gender, proximal 
position, well-differentiated tumors, and mucinous histol-
ogy, but these findings are not consistent.6 Some studies 
have shown a significant coexistence of PIK3CA and KRAS 
mutations, while other studies have failed to show such 
a coexistence. Other contradictory data presented a link 
between the PIK3CA mutation and MSI or CpG island 
methylator phenotype (CIMP).6 Another inconclusive 
study showed worse outcome for early stage resectable 
disease, but other studies did not prove this finding.6 Such 
conflicting findings can be explained by important differ-
ences between cancers that have the mutation in exon 9 vs 
those with the mutation in exon 20.6,7 Exon 20 has a mutual 
relationship with BRAF mutation, CIMP high/low and 
MSI-H, and exon 9 is linked with KRAS mutations.7 In the 
study by Mao et al., authors  showed that mutations in exon 
20 are associated with resistance to anti-EGFR antibody 
therapy. This was not seen for mutations in exon 9.8 Tapia 
et al. reported that PI3K and AKT are overexpressed in GC 
with lymph node spread.9
New molecular classifications of gastric cancer have 
recently been proposed.1,10 We are witnessing huge ad-
vances in our understanding of cancer from a molecu-
lar, immunological, diagnostic and even bioinformatical 
standpoint, all contributing to better tailored treatments 
for patients.1,10−15 In both classifications, microsatellite 
instability (MSI) is a distinct molecular subgroup of GC. 
In the available studies, MSI is associated with older age, 
female gender, intestinal histotype, non-cardia tumors, 
lower number of metastatic lymph nodes, and better sur-
vival.16−18 It seems that the MSI subgroup is not homog-
enous and other genetic and molecular factors may play 
an important role for these particular patients.
The aim of the study was to compare the clinical and 
pathological data of PIK3CA mutation in GC patients. 
We divided PIK3CA mutations into 2 categories based 
on the hotspot mutation sites at exon 9 and exon 20. In ad-
dition, we investigated the coexistence of this mutation 
with MSI status and KRAS mutations.
Material and methods
Patients
The analysis was performed on a group of 472 GC pa-
tients treated in the General Surgery and Surgical Oncol-
ogy Department, University of Siena, Italy. We used tissue 
material stored in our biobank collected from patients 
who were operated on between 1990−2011. None of these 
patients received neoadjuvant treatment. We used tumoral 
and healthy tissues for comparative analysis. All samples 
were collected just after resection in the operating theatre.
PIK3CA sample preparation
Genomic DNA was extracted by tumoral and constitu-
tional fresh frozen sample tissues using a standard protocol 
(Gentra Systems, Minneapolis, USA). The DNA concentra-
tion was calculated by spectrophotometry.
Polymerase chain reaction (PCR) is used for the screen-
ing of PIK3CA (exon 9 and 20).
To search for somatic alterations of the PIK3CA gene, 
exons 9 and 20 were sequenced according to the protocol 
described in detail by Velho et al.19 PCR reactions were 
carried out in a volume of 20 µL containing 100 ng/µL ge-
nomic DNA template, 1X Reaction Buffer, 0.5 µM of each 
PCR primer, MgCl2 1.25 mM, 0.15 mM of each dNTPs, Taq 
polymerase 0.5 U/µL (Euroclone, Pero, Italy). The reactions 
were performed in programmable thermocyclers according 
to the standard protocol.
A 5 µL aliquot of each PCR reaction was run on a 2% aga-
rose gel to confirm the size, quantity, and purity of each PCR 
product. The remaining 15 µL of PCR amplified bands were 
extracted from the gel with the Invisorb® Spin DNA Extrac-
tion Kit (Invitek, Stratec Biomedical Systems, Birkenfeld, 
Germany). Samples were then purified and 2 µL aliquot 
of purified PCR product was cycle sequenced using a Big-
Dye Terminator Kit (Applied Biosystems, Foster City, USA) 
in a total volume of 20 µL. Samples were then purified and 
sequenced using an automated DNA sequencer ABI PRISM 
310 Genetic Analyzer (Applied Biosystems, Milan, Italy) ac-
cording to the protocol of the manufacturer. Sequencing was 
performed in both strands. All sequence alterations in these 
genes were validated with a second independent PCR.
Pentaplex polymerase chain reaction 
and microsatellite analysis
A detailed description of MSI analysis was described in our 
previous paper.18 In short, we used 5 quasi-monomorphic 
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mononucleotide repeats, namely, BAT-26, BAT-25, NR-24, 
NR-21, and NR-27. Following the definition of the National 
Cancer Institute workshop on MSI for cancer, we con-
sidered a tumor as MSI when 2 or more markers showed 
instability on 5 loci (MSI-H).20
A detailed description of the pathological, clinical, sur-
gical and follow-up data was also given in our previous 
publication.18
Statistical analysis
Statistical analysis was performed with the χ2 test 
or Fisher exact test to  compare categorical variables. 
The Mann-Whitney U test was used to compare continu-
ous variables not normally distributed. Cumulative sur-
vival was calculated by the life table method of Kaplan 
and Meier, and the log-rank test was used to distinguish 
significant differences. Statistical significance was deter-
mined at p-value < 0.05.
Survival curves estimated using the Kaplan-Meier meth-
od were compared using a log-rank test, considering death 
from cancer as the end-point (cancer-related survival).
The Kaplan-Meier estimation was used to plot survival 
curves, and log-rank tests were used to calculate the dif-
ference of overall survival (OS) between groups.
Multivariate Cox proportional hazard regression analy-
sis was used to investigate independent prognostic factors 
for overall survival between groups. The variables includ-
ing PIK3CA status, age, sex, tumor location, MSI status, 
Lauren histotype, type of resection, T, N, M status, and ad-
juvant therapy were used as covariates. Statistical analysis 
was done using commercially available statistical software 
(SPSS 20.0 for Windows SPSS Inc., Chicago, USA).
Results
PIK3CA mutation was observed in 10 of 472 GC patients 
(2.1%). Half of the 10 patients had mutations in exon 9 and 
the other half in exon 20. For exon 9 mutations, we found 
2 mutations of E542K, 1 mutation of E545K, 1 of N515S, 
and 1 of E545G. All 5 patients with a mutation in exon 
20 had mutation of H1047R.
Interestingly, 9 of 10 patients were also MSI positive. 
In  2  patients (20%), we observed KRAS mutation and 
PIK3CA mutation in exon 20. Both patient showed KRAS 
mutation -12D and were associated with better prognosis.
A clinicopathological comparison of PIK3CA patients 
and wild-type (wt) PIK3CA patients is presented in Table 1. 
The only statistically significant factor associated with 
PIK3CA mutations was MSI status. We also performed 
an  analysis of  PIK3CA mutation on  the MSI positive 
subgroup. The clinicopathological analysis is presented 
in Table 2. Here, the only statistically significant factor 
was tumor position.
Table 1. PIK3CA wild type vs mutations in all GC group
Clinico-pathological 
characteristic PIK3CA wt PIK3CA mut p-value
Patient (n) 462 10 –
Age (years, median) 70 75 0.058
Sex (male, female) 280:182 (60.6:39.4) 3:7 (30:70) 0.051
pT 0.657
1 42 9.1% 0 0% –
2 74 16% 1 10% –
3 95 20.6% 3 30% –
4 251 54.3% 6 60% –
pN 0.471
0 130 28.1% 3 30% –
1 75 16.2% 2 20% –
2 100 21.6% 4 40% –
3a 74 16% 0 0% –
3b 83 18% 1 10% –
Tumor site 0.256
Non cardia 386 83.5% 7 70% –
Cardia 76 16.5% 3 30% –
MSI status <0.001
MSS 360 77.9% 1 10% –
MSI-H 102 22.1% 9 90% –
Lauren 0.078
Diffuse/mixed 153 33.1% 0 0% –
Intestinal 305 66% 10 100% –
Unclassified 4 0.9% 0 0% –
UICC-R 0.345
R0 339 73.4% 6 60% –
R+ 123 26.6% 4 40% –
Stage 0.389
I 74 16% 1 10% –
II 108 23.4% 3 30% –
III 194 42% 6 60% –
IV 86 18.6% 0 0% –
M 0.131
M0 376 81.4% 10 100% –
M1 86 18.6% 0 0% –
WHO histological type* 0.132
Papillary 15 3.2% 0 0% –
Poorly differentiated 146 31.6% 5 50% –
Signet ring cell & 
mucinous
138 29.9% 0 0% –
Tubular (well/mod. 
diff.)
153 33.1% 4 40% –
Adjuvant 0.406
No 216 46.8% 6 60% –
Yes 246 53.2% 4 40% –
* 11 cases with unclassified WHO histotype are excluded ; MSS – 
microsatellite stable; MSI-H – microsatellite instable; M – metastases;  
pT – pathological tumor status; pN – pathological lymph node status.
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Interestingly all ten patients showed Lauren intestinal 
histotype.
We also analyzed cancer-related survivals. The  first 
comparison was performed between all patients with 
or without PIK3CA mutation (Fig. 1). 5-year survival for 
PIK3CA wt patients was 43.2% and for PIK3CA mutation, 
36% (p = 0.856). Secondly, we analyzed the group of MSI 
GC patients (Fig. 2). The 5-year survival of the MSI pa-
tients presenting with PIK3CA mutation was 40% and 
Fig. 1. Cancer-related survival of patients with or without mutation 
in PIK3CA
Table 2. MSI status patients and PIK3CA mutations
Clinico-
pathological 
characteristic
PIK3CA wt PIK3CA mut p-value
Patient (n) 102 9 –
Age (years, median) 75 76 0.559
Sex (male, female) 44:58 (43.1: 56.9) 2:7 (22.2:77.8) 0.222
pT 0.744
1 5 4.9% 0 0% –
2 20 19.6% 1 11.1% –
3 36 35.3% 3 33.3% –
4 41 40.2% 5 55.6% –
pN 0.309
0 44 43.1% 3 33.3% –
1 18 17.6% 2 22.2% –
2 19 18.6% 4 44.4% –
3a 10 9.8% 0 0% –
3b 11 10.8% 0 0% –
Tumor site 0.008
Non-cardia 99 97.1% 7 77.8% –
Cardia 3 2.9% 2 22.2% –
Lauren 0.069
Diffuse/mixed 28 27.5% 0 0% –
Intestinal 74 72.5% 9 100% –
UICC-R 0.289
R0 83 81.4% 6 66.7% –
R+ 19 18.6% 3 33.3% –
Stage 0.584
I 17 16.7% 1 11.1% –
II 40 39.2% 3 33.3% –
III 36 35.3% 5 55.6% –
IV 9 8.8% 0 0% –
M 0.353
M0 93 91.2% 9 100% –
M1 9 8.8% 0 0% –
WHO histological type* 0.287
Papillary 1 1% 0 0% –
Poorly 
differentiated
42 41.2% 4 44.4% –
Signet ring cell & 
Mucinous
23 22.5% 0 0% –
Tubular (well/mod 
diff.)
34 33.3% 4 44.4% –
Adjuvant 0.756
No 73 71.6% 6 66.7% –
Yes 29 28.4% 3 33.3% –
* 3 cases with unclassified WHO histotype are excluded ;  
MSS – microsatellite stable; MSI-H – microsatellite instability;  
pT – pathological tumor status; pN – pathological lymph node status; 
UICC-R – Union Internationale Contre le Cancer Resection margin.
Fig. 2. Cancer-related survival of patients with MSI status with or without 
PIK3CA mutation
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without the mutation, 70.4% (p = 0.309). We also checked 
the difference in survival of patients with the PIK3CA mu-
tation in different exons (Fig. 3). For mutation in exon 9, 
the 5-year survival was 0% and for mutation in exon 20 
– 80% (p = 0.031). For better visualization of these dif-
ferences between the 2 mutation locations, we added 
a survival curve for MSI patients without PIK3CA muta-
tion (p = 0.026) – Fig. 3.
The  Cox proportional hazards regression analysis 
showed that age, sex, MSI status, “T” parameter, “N” pa-
rameter and type of “R” resection were the only prognostic 
factors statistically correlated with a worse overall survival 
(Table 3).
Discussion
In previous reports, the frequency of GC PIK3CA muta-
tions varies from 4% to 13.2%.21,22 In our paper, PIK3CA 
mutation occurred in 8.1% of the MSI group. In total, only 
a frequency of 2.1% was observed, lower in comparison 
with previous studies. The debate about PIK3CA muta-
tion and its prognosis for different cancers is unresolved. 
Some authors suggest PIK3CA mutation is associated with 
a better prognosis in the case of breast cancer, while other 
authors showed worse prognosis in cancers like colorec-
tal, endometrial, and lung cancers.8,23−25 Warneke et al. 
presented interesting data for gastric cancer, showing 
worse survival in PIK3CA exon 20 mutation with intes-
tinal histotype and better survival for the same mutation 
with diffuse histotype.26 These results were statistically 
significant. In our study, it was impossible to analyze this 
factor because we did not observe diffuse/mixed histotype 
in our sample. PIK3CA mutation in exon 20 was found 
to be an independent prognostic factor of survival for in-
testinal pathology. Also, our results show that mutation 
in exon 20 presented improved patient survival.
In the paper by Fang et al., they found PIK3CA mutation 
in 57/432 of patients (13.2%).22 They analyzed PIK3/AKT 
mutations together and found that in the intestinal his-
totype, patients presenting mutation in that gene showed 
tumors located mostly in the lower third of the stomach. 
In diffuse histotype, the location of the tumor was in the 
upper third of the stomach and patients showed a higher 
rate of hematogenous metastases. The authors did not find 
any difference in survival between patients presenting or 
not presenting PIK3/AKT mutation.
The authors also searched for a link between the PIK3CA 
mutation and Epstein-Barr virus (EBV) infection. The rate 
of EBV infection was higher only in the situation where 
the tumor was situated in the middle part of the stomach 
for GC patients with PIK3CA mutation.22
In a paper by Barbie et al., the authors also analyzed 
PIK3CA mutation in GC and its association with GC and 
MSI.27 Only 8 of 39 MSI GC cases harbored the H1047R 
mutation. They found that this finding did not correlate 
with survival or any other clinical or pathological features 
linked with MSI GC. This is similar to our results on the 
exon 20 mutation in MSI patients, in which similar survival 
results were observed. A worse outcome was only observed 
in the case of exon 9 mutation, which was not observed 
in the above-mentioned study.28
Table 3. Cox proportional hazards regression analysis
Clinico-pathological 
characteristic B Exp (B) 95% CI p-value
PIK3CA −0.113 0.893 0.440–1.815 0.755
MSI status −0.592 0.553 0.405–0.7554 <0.001
Age 0.032 1.032 1.018–1.047 <0.001
Gender 0.363 1.437 1.130–1.829 0.003
Lauren histotype 0.064 1.066 0.823–1.381 0.629
Tumor location 0.027 1.028 0.758–1.394 0.860
“T” parameter 0.602 1.826 1.322–2.522 <0.001
“N” parameter 0.675 1.965 1.354–2.850 <0.001
“M” parameter 0.060 1.062 0.770–1.463 0.715
Radicality of resection 1.098 2.999 2.264–3.972 <0.001
Adjuvant therapy −0.033 0.967 0.683–1.370 0.851
PIK3CA status expressed as PIK3CA wt = 0 and PIK3CA mutation = 1; 
MS status expressed as MSS = 0 and MSI = 1; gender expressed as 
F = 0 an M = 1; Lauren histotype expressed as intestinal = 0 and non-
intestinal = 1; tumor location expressed as non-cardias = 0 and cardias = 1; 
“T” parameter expressed as T1–T2 = 0 and T3–T4 = 1; “N” parameter 
expressed as N− = 0 and N+ = 1; “M” parameter expressed as negative = 0 
and positive = 1; radicality of resection expressed as R0 = 0 and R1–R2 = 1; 
adjuvant therapy expressed as yes = 1 and no = 0;  
MSI status – microsatellite instability; T parameter – pathological tumor 
status; N parameter – pathological lymph node status; M parameter – 
metastases status. 
Fig. 3. Comparison of cancer-related survival of patients with different 
PIK3CA exon mutations together with a survival curve of MSI GC patients 
without PIK3CA mutation
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In our study, we observed that PIK3CA patients were older 
and showed intestinal histotype more often but without sta-
tistical significance. Analyzing the subgroup of MSI GC pa-
tients, the only differences were tumor position (p = 0.008) 
and Lauren histotype (p = 0.069) – PIK3CA mutations were 
more commonly seen in the upper third of the stomach and 
also showed only intestinal histology. We did not observe 
any difference in survival between wild-type and mutated 
PIK3CA GC patients; however, in the MSI GC subgroup 
of patients, those with PIK3CA mutation had a worse 5-year 
survival rate (40%) than those without the mutation (70.4%).
PIK3CA mutations are also observed in head and neck 
squamous cell carcinoma (HNSCC) for 6−21% of patients.4 
Interestingly, this mutation was absent across German, 
Vietnamese, and Greek patients.28,29 Likely, some ethnic, 
environmental, and/or other unknown factors are associ-
ated with this finding. A paper by Seiwert et al. pointed 
out that PIK3CA mutations are more commonly associated 
with human papillomavirus (HPV) positive HNSCC can-
cers.30 This finding did not reach statistical significance 
but can be an example of a factor that may play an im-
portant role in developing this mutation. In our study, we 
observed one of the smallest incidences of PIK3CA muta-
tion in GC patients – 2.1%.
In a CRC study by Day et al., it was found that PIK3CA 
exon 20 mutations were associated with proximal tumors 
and a sessile-serrated pathway (MSI-H/CIMP high/BRAF 
mutations), and PIK3CA exon 9 mutations were linked 
with the traditional serrated pathway of tumorigenesis 
(CIMP-low/KRAS mutations).6 PIK3CA mutations were 
significantly associated with older age, proximal tumor 
site and mucinous histology, and KRAS mutation.6 Com-
parison between wt PIK3CA and either exon 9 or 20 muta-
tions showed some significant results. Mucinous histology 
was associated with exon 20, and for exon 9, factors like 
older age and KRAS mutations were associated. The direct 
comparison of exon 9 and 20 mutations did not reach sta-
tistical significance. In a study by Sukawa et al., MSI status 
was observed in 50% of PIK3CA GC patients.21 Similarly, 
our results show a statistically significant link between 
PIK3CA mutation and MSI status. In fact, almost all of our 
GC patients presenting with a PIK3CA mutation were also 
MSI positive. KRAS mutation was observed only in the 
exon 20 mutation group (2 of 5 patients – 40%).
In breast cancer, PIK3CA mutations are seen in 40% 
of cases.4 The presence of this mutation is associated with 
better prognosis in this cancer. Also, clinicopathological 
factors show higher rates of small tumor size, low grade, 
and positive estrogen receptor much more frequently 
in this group of patients.24 Importantly, these patients also 
showed better survival.24 In other cancers like colorectal, 
endometrial, or lung cancer, PIK3CA mutation is associat-
ed with worse prognosis.23,25 We did not find any difference 
in survival between patients with and without PIK3CA 
mutations. The difference was observed when we analyzed 
subgroups according to the type of exon mutation.
Our study was limited by the small number of patients 
with PIK3CA mutations in our GC patient pool. We pre-
sented a link between different PIK3CA exon mutations 
and MSI GC that present completely different prognoses 
depending on the type of mutation. The MSI subtype of GC 
is a relatively new molecular subgroup and requires further 
analysis of different mutations that may have a positive or 
negative impact on patient outcome.
Our research leads to some important conclusions about 
PIK3CA mutations. Firstly, PIK3CA mutations in  GC 
is rare. It is strongly associated with the MSI molecular 
subgroup, presenting a worse outcome than wt PIK3CA 
MSI GC patients. A completely different outcome is asso-
ciated with mutation in exon 9 vs exon 20, with the latter 
being more favorable. The role of this mutation must be 
further studied with larger groups of patients.
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